Kygevvi Approved in EU for Rare TK2d Deficiency & Rezurock for Chronic GvHD

The news coming out of Europe this week – the European Commission’s approval of UCB’s Kygevvi as the first treatment for thymidine kinase 2 deficiency (TK2d) – might seem distant to many here in Austin, Texas. But for the minor, yet critically impacted, community facing ultra-rare genetic diseases, it’s a beacon of hope and a signal of a shifting landscape in pharmaceutical innovation. The approval, granted “under exceptional circumstances,” underscores the growing recognition of the need to address conditions that, even as individually rare, collectively represent a significant burden on families and healthcare systems.

Kygevvi (doxecitine and doxribtimine) offers a potential lifeline to individuals with TK2d whose symptoms began before the age of 12. Donatello Crocetta, UCB’s chief medical officer, rightly calls this a “historic milestone.” TK2d is a devastating mitochondrial myopathy, a progressive and life-threatening condition stemming from mutations in the TK2 gene. This genetic defect leads to a depletion of mitochondrial DNA, resulting in severe muscle weakness that can rapidly become fatal – sometimes within just three years of symptom onset. Imagine the challenges faced by families navigating this diagnosis, often misidentified initially as other neuromuscular disorders like spinal muscular atrophy.

The difficulty in pinpointing the exact number of TK2d patients adds to the complexity. Symptoms can mimic other conditions, leading to delayed or inaccurate diagnoses. However, recent research suggests an estimated prevalence of around 500 patients in the top four EU economies and the UK, with a comparable number in the United States. This underscores the global nature of rare diseases and the importance of international collaboration in research and treatment development. UCB’s drug received FDA approval last November, paving the way for access in the US, and now, with the European Commission’s approval, a broader patient population can potentially benefit.

The clinical trial data supporting Kygevvi’s approval is particularly compelling. The drug demonstrated a remarkable 95% reduction in the risk of death compared to untreated patients. This isn’t just a marginal improvement; it’s a transformative outcome for a disease with historically limited treatment options. The analysis revealed that 84% of patients treated with Kygevvi experienced a regain of one or more motor functions, with 22% even able to discontinue respiratory support. These gains represent a significant improvement in quality of life for individuals and families grappling with the debilitating effects of TK2d.

A Parallel Path: Sanofi’s Rezurock and the Challenges of EU Approval

While Kygevvi’s approval represents a clear success story, the journey isn’t always straightforward. The recent EU clearance of Sanofi’s Rezurock for chronic graft-versus-host disease (GvHD) highlights the hurdles pharmaceutical companies can face in navigating the European regulatory landscape. Rezurock was initially turned down last October, five years after receiving approval in the US. This delay underscores the complexities of the EU approval process and the need for robust clinical data to demonstrate efficacy and safety.

Rezurock’s approval is conditional, requiring Sanofi to conduct further clinical trials to confirm its effectiveness. Here’s a common practice for novel therapies, particularly those addressing complex conditions like GvHD, where treatment options are limited. GvHD occurs when donor cells attack the recipient’s organs after a transplant, and it can be a debilitating and life-threatening complication. The fact that nearly half of chronic GvHD patients require third-line treatment, yet face limited options, emphasizes the urgent need for innovative therapies like Rezurock. Sanofi’s acquisition of Kadmon Pharma in 2021, which included Rezurock, demonstrates the strategic importance of expanding portfolios to address unmet medical needs.

Olivier Charmeil, Sanofi’s interim chief executive, emphasized the significance of the approval, noting the limited therapeutic options available for EU patients at the late stages of GvHD. This sentiment resonates with the broader conversation surrounding rare diseases and the importance of fostering innovation to address these often-overlooked conditions.

Navigating Rare Disease Support in the Austin Area

Given my background in genetic counseling and my understanding of the challenges families face when navigating rare disease diagnoses, if these developments impact you or a loved one in the Austin area, here are three types of local professionals you should consider connecting with:

• Genetic Counselors: Look for board-certified genetic counselors with experience in neuromuscular disorders. They can help interpret genetic testing results, understand inheritance patterns, and provide emotional support. Specifically, seek counselors affiliated with Dell Children’s Medical Center or UT Health Austin, as they often have specialized expertise in rare genetic conditions.
• Neuromuscular Specialists: A neurologist specializing in neuromuscular disorders is crucial for diagnosis and ongoing management. Prioritize physicians affiliated with Ascension Seton Neurological Institute or Baylor Scott & White Healthcare – Austin, as these institutions have dedicated neuromuscular centers with access to advanced diagnostic tools and treatment options.
• Rare Disease Advocates/Patient Navigators: Organizations like the National Organization for Rare Disorders (NORD) have local chapters and can connect you with patient navigators who can assist with accessing resources, financial assistance programs, and support groups. Explore local support groups facilitated through the Texas Rare Disease Coalition.

Ready to find trusted professionals? Browse our complete directory of top-rated healthcare experts in the Austin area today.